Excedrin relaunched in the United States in 2013 and is doing well. The brand generated $130 million between its Excedrin tablets and Excedrin Migraine tablets for the 52 weeks ended June 15 across total U.S. multi-outlets, according to IRI.
Perfecta Products last year added Zim’s Arnica Max to it’s lineup of external analgesic rubs, which includes Zim’s Max-Freeze, an $11.8 million brand grew 27.3% for the 52 weeks ended June 15 across total U.S. multi-outlets, according to IRI.
The entire external analgesic category is up 6.7%, reaching a base of $486.9 million across total U.S. multi-outlets for the 52 weeks ended June 15, according to IRI data. And Salonpas, with a 10.9% dollar share, is helping to drive that growth with positive sales gains of 28.7% to $52.9 million.
The lion’s share of the analgesics business may be in internal analgesics — sales of which totaled $3.6 billion, up 1.1% for the 52 weeks ended June 15 across total U.S. multi-outlets, according to IRI — but it’s alternative pain relievers that may represent the growth opportunity.
Despite creating a detailed plan to speed up the rate at which generic drug applications are reviewed, experts say a backlog has developed at the Food and Drug Administration’s Office of Generic Drugs.
“It’s not enough to pull drowning victims out of the river. You have to walk upstream to find out who’s throwing them in.” Physician and educator David Kilgore invoked that piece of wisdom from Episcopal bishop V. Gene Robinson to describe the current state of medicine in the United States — and the steps needed to drag the nation’s outmoded, costly and inefficient healthcare system into the 21st century.
Despite a rocky start, the full rollout of health reform under the Affordable Care Act has already brought major benefits to the nation’s troubled health system and affordable coverage to millions of formerly uninsured or underinsured Americans, one of the Obama administration’s top health officials asserted recently.
“We have a system that needs fixing.” That comment on the state of the nation’s healthcare system, shared by physician and New York Times correspondent and senior writer Elisabeth Rosenthal, served as the springboard for a high-level summit on the future of health care in the United States. The event drew a who’s who of nationally known health experts, scientists and government officials.